Shanghai Likangrui Biology Engineering

Shanghai Likangrui Biological Engineering is a biopharmaceutical subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. (SPH), established in 2011. The company is dedicated to the research, development, and industrialization of high-end biological products, with a primary focus on recombinant proteins and vaccines. Its most prominent project is the development of recombinant human serum albumin (rHSA), which serves as a critical alternative to plasma-derived products for treating conditions like hypoalbuminemia. Additionally, Likangrui is a key player in the production of the Enterovirus 71 (EV71) vaccine to combat hand, foot, and mouth disease. The company operates a large-scale, GMP-compliant manufacturing base in Shanghai, supporting SPH's broader strategy in the biological medicine sector.